SEC Filings

Show all

Stock Information

: (Common Stock)

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Corporate Governance

The Board of Directors of Selecta Biosciences sets high standards for the company’s employees, officers, and directors.
Implicit in this philosophy is the importance of sound corporate governance.

Events
Featured Reports
Apr 28, 2021
2020 Proxy Statement
Mar 12, 2021
2020 Annual Report

Press Releases

26 Jul
Selecta Biosciences Announces Appointment of Jude Samulski, Ph.D. as Gene Therapy Special Advisor and the Publication of Data Evaluating ImmTOR™ with AAV vectors for the treatment of Methylmalonic Acidemia
– Selecta appoints gene therapy pioneer Jude Samulski , Ph.D. as a special advisor to help guide Selecta’s gene therapy programs into the clinic – – Data demonstrate that ImmTOR enhances transgene expression after both initial and repeat dosing – –  Publication further validates use of ImmTOR in
08 Jul
Selecta Biosciences to Participate at the William Blair Biotech Focus Conference 2021
WATERTOWN, Mass. , July 08, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief
24 Jun
Selecta Biosciences Appoints Industry Leader Nishan de Silva, M.D. to Board of Directors
WATERTOWN, Mass. , June 24, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences , Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced   the appointment of
16 Jun
Selecta Biosciences to Participate at the Raymond James Human Health Innovation Conference
WATERTOWN, Mass. , June 16, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief
Stock Information
Stock Information
Information Request
Information Request
Financial Information
Financial Information
FAQ
FAQ